A comparison of 111In-DOTATOC and 111In-DOTATATE: Biodistribution and dosimetry in the same patients with neuroendocrine tumours

F. Forrer, H. Uusijärvi, C. Waldherr, M. Cremonesi, P. Bernhardt, J. Mueller-Brand, H. R. Maecke

Research output: Contribution to journalArticlepeer-review

Abstract

[Yttrium-90-DOTA-Tyr3]-octreotide (DOTATOC) and [ 177Lu-DOTA-Tyr3-Thr8]-octreotide (DOTATATE) are used for peptide receptor-mediated radionuclide therapy (PRMRT) in neuroendocrine tumours. No human data comparing these two compounds are available so far. We used 111In as a surrogate for 90Y and 177Lu and examined whether one of the 111In-labelled peptides had a more favourable biodistribution in patients with neuroendocrine tumours. Special emphasis was given to kidney uptake and tumour-to-kidney ratio since kidney toxicity is usually the dose-limiting factor. Five patients with metastatic neuroendocrine tumours were injected with 222 MBq 111In-DOTATOC and 111In-DOTATATE within 2 weeks. Up to 48 h after injection, whole-body scans were performed and blood and urine samples were collected. The mean absorbed dose was calculated for tumours, kidney, liver, spleen and bone marrow. In all cases 111In-DOTATATE showed a higher uptake (%IA) in kidney and liver. The amount of 111In-DOTATOC excreted into the urine was significantly higher than for 111In- DOTATATE. The mean absorbed dose to the red marrow was nearly identical. 111In-DOTATOC showed a higher tumour-to-kidney absorbed dose ratio in seven of nine evaluated tumours. The variability of the tumour-to-kidney ratio was high and the significance level in favour of 111In-DOTATOC was P=0.065. In five patients the pharmacokinetics of 111In-DOTATOC and 111In-DOTATATE was found to be comparable. The two peptides appear to be nearly equivalent for PRMRT in neuroendocrine tumours, with minor advantages for 111In/90Y-DOTATOC; on this basis, we shall continue to use 90Y-DOTATOC for PRMRT in patients with metastatic neuroendocrine tumours.

Original languageEnglish
Pages (from-to)1257-1262
Number of pages6
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume31
Issue number9
DOIs
Publication statusPublished - Sep 2004

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Fingerprint Dive into the research topics of 'A comparison of 111In-DOTATOC and 111In-DOTATATE: Biodistribution and dosimetry in the same patients with neuroendocrine tumours'. Together they form a unique fingerprint.

Cite this